

Gary M. Nath
Registration Number 26,965
Tanya E. Harkins
Registration Number 52,993
Customer Number 20529



Attorney Docket: 26465U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner: Unknown

LOOS

Group Art Unit: Unknown

International Application Number: PCT/EP03/06435

Serial Number: 10/518,413

International Filing Date: 18 June 2003 (18.06.2003)

Filed: December 17, 2004

For: **METHOD FOR DIAGNOSING AND TREATING NIS-EXPRESSING CARCINOMAS
AND METASTASES**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars:

- [NOTE: One only of items a, b, c, and d must be checked.]
- [**XXX**] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a

notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

- ☐ Certification report(e) below; and
- ☐ a check in the amount as required by 1.17(p).

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
or

☐ Appropriate certification is attached.

[~~xxx~~] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

☐ g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or
☐ Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

or
[~~xxx~~] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.


If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: March 3, 2005

By:



Gary M. Nath
Registration Number 26,965
Tanya E. Harkins
Registration Number 52,993
Customer Number 20529

NATH & ASSOCIATES PLLC
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005-1503
(202) 775-8383
GMN/TEH/le

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket:
26465U

Serial Number: 10/518,413

Filing Date: December 17, 2004

Inventor:
LOOSInternational Application Number:
PCT/EP03/06435Group Art Unit:
UnknownInternational Filing Date:
18 June 2004

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
A1						

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-Class	Translation
A2	02/055688 A2	18 Jul. 2002	WO			N/A
A3	198 05 788 A1	19 Aug. 1999	DE			No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A4	Elstner, E., et al., "Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells <i>in vitro</i> and in BNX mice", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, Pp. 8806-8811, (1998).
A5	Mehta, R.G., et al., "A Ligand of Peroxisome Proliferator-Activated Receptor γ , Retinoids, and Prevention of Preneoplastic Mammary Lesions", <u>Journal of the National Cancer Institute</u> , Vol. 92, No. 5, Pp. 418-423, (2000).
A6	Sato, M., et al., "Synergistic Potentiation of Thiazolidinedione-Induced ST 13 Preadipocyte Differentiation by RAR Synergists", <u>Biochemical and Biophysical Research Communications</u> , Vol. 280, Pp. 646-651, (2001).
A7	Westin, S., et al., "Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators", <u>Nature</u> , Vol. 395, Pp. 199-202, (1998).
A8	Schulman, I.G., et al., "Transactivation by Retinoid X Receptor-Peroxisome Proliferator-Activated Receptor γ (PPAR γ) Heterodimers: Intermolecular Synergy Requires Only the PPAR γ Hormone-Dependent Activation Function", <u>Molecular and Cellular Biology</u> , Vol. 18, No. 6, Pp. 3483-3494, (1998).
A9	Kogai, T., et al., "Differential Regulation of the Human Sodium/Iodide Symporter Gene Promoter in Papillary Thyroid Carcinoma Cell Lines and Normal Thyroid Cells", <u>Endocrinology</u> , Vol. 142, No. 8, Pp. 3369-3379, (2001).
A10	Filetti, S., et al., "Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism", <u>European Journal of Endocrinology</u> , Vol. 141, Pp. 443-457, (1999).
A11	Kitazono, M., et al., "Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na ⁺ /I ⁻ Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells", <u>The Journal of Clinical Endocrinology & Metabolism</u> , Vol. 86, No. 7, Pp. 3430-3435, (2001).
A12	Tanosaki, S., et al., "Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cancer cells", <u>Breast Cancer Research and Treatment</u> , Vol 79, Pp. 335-345, (2003).

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.